Synairgen
(‘Synairgen’ or the ‘Company’)
John Bradshaw appointed as independent Non-Executive Director
Southampton, UK – 29 April 2025: Synairgen, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, provides an update post its recent General Meeting held on 28 March 2025.
The company today announces the appointment of John Bradshaw to the Board as an independent Non-Executive Director and Chair of the Audit Committee, effective 1 May 2025.
Mr Bradshaw is a Chartered Accountant with more than 30 years post-qualification experience working at Board level in UK listed companies, venture capital backed companies and partnerships including Chair of Audit Committee for two AIM listed companies and Chief Financial Officer of Syncona Investment Management Limited, the investment manager of Syncona Limited, a FTSE250 healthcare investment company.
Mark Parry-Billings, Chairman of the Board of Synairgen, said: "I am delighted to welcome John to the Synairgen Board. His very significant track record of success in the biotech sector and his financial expertise and acumen, will be very positively impactful for our Company, not least as we prepare to begin our large Phase 2 INVENT trial in mechanically-ventilated patients with viral pneumonia”
John Bradshaw, Non-Executive Director of the Board of Synairgen, commented: “Joining Synairgen’s Board at this pivotal stage for the Company gives me the opportunity to work with the team to drive forward this potentially transformative treatment for a patient group with high unmet medical need."
For further enquiries, please contact:
Synairgen | + 44 (0)23 8051 2800 |
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.
For more information about Synairgen, please see www.synairgen.com